Sotrovimab Treatment for COVID-19 Effective in a B-Cell-Depleted Patient after Anti-CD20 Treatment.

Kazuyuki Murase,Kohichi Takada,Yohei Arihara,Koji Miyanishi,Junji Kato
DOI: https://doi.org/10.7759/cureus.41486
2023-01-01
Abstract:Patients with hematologic malignancies are well known to have prolonged COVID-19 pneumonia. The cause has been reported to be B cell depletion after administration of anti-CD20 antibodies. Here, we report a case of COVID-19 pneumonia due to prolonged B-cell depletion after anti-CD20 antibody therapy for malignant lymphoma two years before. Sotrovimab, a neutralizing antibody that was designed to prevent the progression of COVID-19, was successful in preventing the progression to severe disease in this B-cell-depleted patient.
What problem does this paper attempt to address?